LONDON, June 28, 2016 /PRNewswire/ --

Assessment of Top Companies Including AbbVie, Amgen, Johnson & Johnson and Pfizer, Analysis of Leading National Markets (the US, Japan, EU5 and BRIC), Exploration of Current Products Including Humira, Enbrel, Other Anti-TNFs, Anti-IL17s, Anti-IL23, PDE4 Inhibitor and Biosimilars, and Evaluation of the R&D Pipeline Including New Biologics, Oral Small Molecules and Topical Therapies 

Psoriasis Drugs - Your Guide to R&D, Opportunities and Potential Revenues

What does the future hold for treating psoriasis? Visiongain's new report gives you multilevel revenue forecasts from 2016, helping you stay ahead in data. There you see financial results, R&D trends, opportunities and potential revenues.

In our study you examine predicted sales to 2026 at overall world market, submarket, product and national level. You also assess technologies, competitive forces and expected products. That work's purpose is to help you avoid falling behind in knowledge, missing business or losing influence.

So read on now to explore that industry and discover what its future market could be worth. See how our investigation can benefit your work.

Forecasts from 2016 to 2026 and other analyses to help you harness opportunities
Why miss data you need? Why struggle to find it? Instead let our analysis guide you through the psoriasis drug market's present and future. That understanding could bring you quicker, easier results, also benefiting your influence and reputation for business insight.

Besides revenue forecasting to 2026, our new work shows you recent results, growth rates and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). In our 169 page study you gain 74 tables and 63 charts to benefit your research, analyses, plans, decisions and presentations.

The following sections outline what you get in our updated investigation.

Sales predictions for the world market and submarkets
What is that industry's potential? Discover in our report overall world revenue to 2026 for psoriasis-treating medicines. First you see individual revenue forecasts to 2026 for three main submarkets at world level:
• Biological drugs
• Topical treatments
• Small-molecule systemic therapies.

How will those segments' revenues expand? Which classes of treatment will generate most sales? There you assess prospects for revenue growth, seeing where you can gain, assessing how that industry will compete and develop.

You find revenue predictions by product, too, seeing from 2016 how they can succeed.

Revenue predictions for 13 products to 2026 - discover what their futures hold
How will individual drugs perform from 2016 to 2026 at world level? Our report forecasts revenues of established brands and medicines expected from 2016.

In our work you assess 13 drugs, including these brands:
• Humira (adalimumab)
• Stelara (ustekinumab)
• Enbrel (etanercept)
• Remicade (infliximab)
• Otezla (apremilast)

There you discover how high sales can go, to 2026, finding drugs and years with highest predicted growth and revenues. You also examine trends and competition. You see what is happening, understanding challenges, progress, competitors and opportunities.

You find geographical revenue predictions too.

National markets - where will highest revenues and growth occur?
In developed and developing countries, opportunities in psoriasis treatment will occur from 2016. You see where and how pharma companies can develop and gain.

Our analyses show individual revenue forecasts to 2026 for these 11 national markets:
• US and Japan
• France, Germany, Italy, Spain and UK
• Brazil, Russia, India and China.

There you find countries with highest revenues and potential sales growth. You assess that technology's future, seeing progress and finding what it means, including emerging trends for those skin disorder treatments.

Events affecting developers, producers and sellers - issues shaping that industry
Our report explains forces affecting that industry and market from 2016, including these influences:
• Research and development, including monoclonal antibodies, IL-12, IL-17, IL-23, PDE4, TNF, JAK and T-cell inhibition, and histamine receptor antagonism
• Prevalence of that skin disease, as well as issues for patients and healthcare providers - assess treatment needs
• Competition from generic drugs, biosimilars and new biologics
• Companies specialising in dermatology and autoimmune disorders - explore capabilities and emerging trends to treat psoriasis
• Advances in drug delivery to benefit companies, patients and payers, including lotion, ointment and foam.

In our survey you explore political, economic, social and technological questions, assessing outlooks for business. You also examine that pharmaceutical segment's strengths, weaknesses, opportunities and threats.

That way you discover what the present and future hold, seeing what is possible for those drug developers, producers and marketers. Stay ahead in knowledge.

Companies leading that industry and our overall revenue prediction for 2020
From 2016, treatments for psoriasis hold potential for investments, medical advances and higher revenues. Our work predicts the overall world market for psoriasis medicines will reach $11.4bn in 2020, with further expansion to 2026.

See what is possible there - the expected gains. Our report shows you what technologies and firms hold greatest potential. You explore activities of these companies, among others:
• Johnson & Johnson
• AbbVie
• Amgen
• Pfizer
• Novartis
• Celgene
• LEO Pharma.

Our analysis shows you participants' results, capabilities, developments and outlooks. R&D in that industry is strong. From 2016 the psoriasis market holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead in knowledge.

Main ways Psoriasis Drugs Market Forecasts 2016-2026 helps your work
In particular our new investigation gives you these advantages to benefit your research, analyses, decisions, proposals and presentations:
• Revenues to 2026 at world level, with forecasting of 3 submarkets and 13 products - assess prospects for investments and sales growth
• Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia - investigate leading countries for revenues and expected sales
• Forces driving and restraining that industry's expansion - discover what influences revenue gain, finding trends, developments and opportunities
• Prospects for established competitors and rising companies - explore companies' portfolios, results, R&D and outlooks for future success.

Information found nowhere else: see how you can gain - why miss out?
Our investigation gives you independent analysis. There you gain business intelligence found only in our work, finding where opportunities for revenue expansion exist.

See in our work how you could benefit your research, analysis and decisions. Explore progress and possibilities. Also find how you could save time and benefit your authority on those drugs, helping your reputation for commercial insight.

Medicines for psoriasis - get revenue predictions now, seeing what the future holds
Our new report is for everyone investigating drugs for inflammation and skin disorders. In our survey you explore revenue forecasts to 2026, with discussions and other data. Avoid missing out in knowledge - instead please get our report here now.

Companies mentioned 

Abbott Laboratories
AbbVie Inc
Alcon
Allergan, PLC
Amgen
AstraZeneca (AZ)
Biogen Inc
Boehringer Ingelheim
Brazilian Ministry of Health
Bristol-Myers Squibb (BMS)
Can-Fite BioPharma
Celgene Corporation
Cellceutix Corporation
Celltrion
Center for Drug Evaluation (China)
Centocor Ortho Biotech Inc
Cipla Ltd
Coherus BioSciences
Committee for Medicinal Products for Human Use (CHMP)
Daiichi Sankyo Co Ltd
Dermira
Eisai Co Ltd
Eli Lilly and Company
European Medicines Agency (EMA)
Epirus Biopharmaceuticals
European Union (EU)
Food and Drug Administration (FDA)
G & W Laboratories
Glaxo Wellcome
GlaxoSmithKline (GSK)
Hospira
Immunex Corporation
Incyte Corporation
Janssen Biotech Inc
Janssen Pharmaceutical Companies
Japanese Ministry of Health, Labour and Welfare
Johnson & Johnson (J&J)
Kyowa Hakko Kirin Co Ltd
LEO Pharma A/S
Maruho Co Ltd
Merck & Co Inc
Merck Sharp & Dohme (MSD)
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals Inc
MorphoSys AG
Mylan
Nippon Kayaku Co Ltd
Novartis International AG
Pfizer Inc
Ranbaxy Laboratories Ltd
Samsung Bioepis
Sandoz
Sanofi SA
Servier Laboratories
Shanghai CP Guojian Pharmaceutical Co. Ltd
Sistema Único de Saúde (SUS)
SmithKline Beecham
South Korean Ministry of Food and Drug Safety
Stiefel Laboratories
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Therapeutics Inc
UCB
Valeant Pharmaceuticals International Inc
World Bank
Wyeth
Zydus Cadila

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/report_license.aspx?rid=1669

SOURCE Visiongain Ltd